December 24, 2011 -- Hutchison MediPharma and AstraZeneca formed a partnership to develop a novel cancer molecule; Hua Medicine in-licensed global rights to diabetes treatment program; Shunfeng Pharma is auctioning itself off to the highest bidder, which is expected to be Sanjiu Medical; Beijing Double-Crane Pharma will pay $17.4 million to buy Henan Shuanghe Huali Pharma; Beijing SL Pharma and Lin Chia announced a US-based JV; ForteBio, a maker of biotech drug development tools, was acquired by Pall Corporation; BioTime optioned antibody-producing cell lines from USCN Life Science China; Frontage Labs opened a renovated clinical-stage facility for cancer in Jilin University Hospital; Jiangsu Hengrui Medicine was granted FDA approval for a chemotherapy drug; and DSM Sinochem announced plans to build a manufacturing facility in Shandong province. More details….
Stock Symbols: (NYSE: AZN) (SIX: ROG) (SHE: 000999) (SHA: 600062) (SHE: 002038) (NYSE: PLL) (AMEX: BTX) (SHA: 600276)
